Evaluation of a Novel Insulin Sensitizer in People With Type 1 Diabetes

Official title

Evaluation of a Novel Insulin Sensitizer on Glycemic Control, Insulin Usage, and Cardiovascular Biomarkers in People With Type 1 Diabetes Who Use Closed-loop Automated Insulin Delivery

Overview

The purpose of this study is to see if the study drug CIR-0602K will improve glucose time-in-range and/or lower total daily insulin dose in people with type 1 diabetes who are using closed-loop automated insulin delivery. Researchers will compare CIR-0602K to a placebo (a look-alike substance that contains no drug) to see if it achieves the investigational endpoints. If the study results show that the drug works to increase time-in-range and lower insulin doses, this will lead to further studies which may then make the drug available to the public.

Detailed description

Participants in the study will:

* Come to the Clinical Research Unit (CRU) at UVA Medical Center for 3 visits: Screening, Baseline (Admission 1) and End-of-Study (Admission 2). * Complete various tests of cardiovascular health at each visit. * Take either an experimental drug (CIR-0602K) or placebo for 12 weeks. * Wear a study CGM with their personal insulin pump for 12 weeks. * Be given a ketone meter and strips and be asked to take a fingerstick ketone reading every morning for 12 weeks. * The study team will contact the participants regularly during the study to check their health and how they are tolerating the study drug/placebo. * Return the study CGM, ketone meter, and remaining supplies, etc. at the end of the study. * Notify the study team of any illness, injury, hypoglycemic or hyperglycemic events during the study

Interventions

• Drug CIR-0602K
  mitochondrial pyruvate carrier inhibitor
• Drug Placebo
  Placebo tablet

Primary outcome measures

• Glucose Time-in-Range [Time frame: 12 weeks]

Secondary outcome measures (5)

• Total Daily Insulin Dose [Time frame: 12 weeks]
• Glucose Time-above-Range [Time frame: 12 weeks]
• Glucose Time-Below-Range [Time frame: 12 weeks]
• Hemoglobin A1c [Time frame: 12 weeks]
• Insulin Sensitivity [Time frame: 12 weeks]

Eligibility criteria

Inclusion criteria

• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study
• History of type 1 diabetes for at least one year
• Age 18-45 years
• HbA1c <10%

• BMI 18-35 kg/m2. Within this criterion, participants must have either BMI ≥25 or total daily insulin dose of ≥0.5 units/kg/day.
• Currently utilizing closed-loop AID therapy that is compatible with Dexcom G7 CGM.
• On stable regimen of non-diabetic medications for the last 6 months.
• All screening labs within normal limits or not clinically significant.
• Ability to take oral medication and be willing to adhere to the study drug/placebo for 12 weeks.
• For females and males of reproductive potential: agreement to use adequate contraception during study participation and for an additional 2 weeks after the end of CIR-0602K administration.
• For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study intervention.
• Agreement to adhere to Lifestyle Considerations throughout study duration.

Exclusion criteria

• Current Pregnancy or currently breastfeeding.
• History of smoking tobacco products within the last two years.
• History of alcohol abuse or illicit drug abuse within 6 months of screening.
• Known history of human immunodeficiency virus (HIV).
• History of other significant disease (e.g., cardiac, cerebrovascular, gastrointestinal, liver, renal, or endocrine) that could, in the investigator's view, alter study outcomes
• Any surgical or medical condition which may significantly alter the absorption of the study drug including but not limited to the following: history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel resection, gastric bypass, gastric stapling, or gastric banding, currently active inflammatory bowel syndrome.
• Current use of any antihyperglycemic medication beyond insulin (i.e., GLP-1 receptor agonists, SGLT2 inhibitors, etc.).
• Unstable doses (i.e., dose change within the last 4 months) of vasoactive medications (e.g., calcium-channel blockers, statins, angiotensin-converting enzyme inhibitors, diuretics, nitrates, alpha-blockers, beta-blockers, etc.).
• Daily use of anti-inflammatory medications (e.g., ibuprofen, aspirin, prednisone, dexamethasone, etc.).
• Diagnosis of peripheral neuropathy (assessed by screening monofilament exam).
• Macroalbuminuria (i.e., urine albumin: creatinine >300 mg per g).
• Retinopathy beyond mild, nonproliferative retinopathy.
• History of Level 3 hypoglycemia within the last 12 months.
• History of diabetic ketoacidosis (DKA) within the last 12 months.
• Screening electrocardiogram (ECG) findings indicative of arrhythmia, sinus node disease, or ischemic heart disease.
• Screening oxygen saturation <90%
• History of hypersensitivity or prior adverse reaction to the study drug, closely-related compounds, or any of the stated ingredients.
• Use of concomitant medications with a known significant metabolism by CYP2C8 or CYP2C (including paclitaxel, phenytoin, warfarin, celecoxib, tolbutamide, or repaglinide) for the duration of the study.
• Participation in an investigational study (other than a non-treatment registry study) or received an investigational drug withing 30 days or 5 half-lives (whichever is longer) prior to randomization.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Quadruple blind

Primary purpose

Treatment

Study locations

United States · 1 center

• University of Virginia — Charlottesville

Identifiers

NCT: NCT07186660 · 302645 · 3-SRA-2025-1773-M-B

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗